Shares of diabetes and glucose monitoring stocks are trading lower. The sector may be down on the FDA's announcement of a Digital Health Advisory Committee as well as early signs of efficacy in Novo Nordisk's Ozempic kidney trial. The sector has been under pressure this year amid the popularity of weight loss drugs.
Portfolio Pulse from Benzinga Newsdesk
Diabetes and glucose monitoring stocks are trading lower due to the FDA's announcement of a Digital Health Advisory Committee and early signs of efficacy in Novo Nordisk's Ozempic kidney trial. The sector has been under pressure this year due to the popularity of weight loss drugs.
October 11, 2023 | 7:38 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Dexcom's stock is trading lower due to regulatory changes and competition from Novo Nordisk's Ozempic kidney trial.
The FDA's new Digital Health Advisory Committee could potentially introduce new regulations that may affect Dexcom's operations. Additionally, the efficacy of Novo Nordisk's Ozempic kidney trial could pose a threat to Dexcom's market share in the diabetes and glucose monitoring sector.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 75
NEGATIVE IMPACT
Insulet Corporation's stock is trading lower due to regulatory changes and competition from Novo Nordisk's Ozempic kidney trial.
The FDA's new Digital Health Advisory Committee could potentially introduce new regulations that may affect Insulet Corporation's operations. Additionally, the efficacy of Novo Nordisk's Ozempic kidney trial could pose a threat to Insulet's market share in the diabetes and glucose monitoring sector.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 75
NEGATIVE IMPACT
Tandem Diabetes Care's stock is trading lower due to regulatory changes and competition from Novo Nordisk's Ozempic kidney trial.
The FDA's new Digital Health Advisory Committee could potentially introduce new regulations that may affect Tandem Diabetes Care's operations. Additionally, the efficacy of Novo Nordisk's Ozempic kidney trial could pose a threat to Tandem's market share in the diabetes and glucose monitoring sector.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 75